Asimov’s CHO Edge System, including the recently announced Chrysalis transposase and Kernel, Asimov’s AI-driven genetic design software, will support LG Chem’s biologics cell line development activities 

‍

BOSTON, MA, October 21, 2026–Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a licensing agreement with South Korea-based LG Chem, a leading global chemical company with a diversified business portfolio spanning across petrochemicals, advanced materials, and life sciences. Through this partnership, LG Chem will in-license Asimov’s CHO Edge System to support biologics cell line development activities. 

‍

“Drug developers are exploring a wider therapeutic design space than ever before, and it’s led to an explosion of complex molecules, from multispecific antibodies to fusion proteins to antibody drug conjugates,” said Alec Nielsen, co-founder and CEO at Asimov. "LG Chem is at the forefront of this wave of innovation, and we are proud they have chosen to adopt our CHO Edge System as a key enabler of their next generation of therapeutic biologics.”

‍

About Asimov

Asimov’s mission is to advance humanity’s ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform—from cells to software—to design and manufacture next-generation therapeutics, including biologics, cell and gene therapies, and RNA through a combination of products, services, and collaborations. 

‍

Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. For more information, visit www.asimov.com.

‍

About LG Chem, Ltd. and LG Chem Life Sciences

LG Chem is a leading global chemical company with a diversified business portfolio spanning across petrochemicals, advanced materials, and life sciences. LG Chem Life Sciences, the life sciences business division of LG Chem, is dedicated to developing and delivering innovative medicines across a broad range of therapeutic areas. Guided by its mission to transform people's lives through inspiring science and leading innovation, LG Chem Life Sciences is offering differentiated solutions to its customers. For more information, please visit www.lgchem.com.

‍

Highlights

  • Virtual Private Network (VPN): Users connect to the cluster, provide some credentials and are then able to access internal tools.
  • Single Sign-On: A tool like Kerberos allows you to use the same account across various components.
  • Home-grown user accounts: You implement an authentication system and users have a separate username/password for your computing infrastructure.

Asimov, the synthetic biology company building a full-stack platform to program living cells, announced today it has been awarded a contract as part of the Defense Advanced Research Projects Agency (DARPA) Automating Scientific Knowledge Extraction (ASKE) opportunity.

Through ASKE, Asimov will work to develop a physics-based artificial intelligence (AI) design engine for biology. The goal of the initiative is to improve the reliability of programming complex cellular behaviors.

“To achieve truly predictive engineering of biology, we require dramatic advances in computer-aided design. Machine learning will be critical to bridge genome-scale experimental data with computational models that accurately capture the underlying biophysics. As genetically engineered systems grow in complexity, they become difficult for humans to design and understand. For simple genetic systems with only a couple of genes, synthetic biologists typically use high-throughput screening and basic optimization algorithms. But to engineer more complex applications in health, materials, and manufacturing, we need radically new algorithms to intelligently design the DNA and simulate cell behavior.”

Alec Nielsen, Phd, Asimov CEO
Over the past 50 years, DARPA has been a world leader in spurring innovation across the field of AI, including statistical-learning and rule-based approaches. We are proud to work with DARPA to advance the state-of-the-art in AI-assisted genetic engineering.

Asimov’s founders previously built a hybrid genetic engineering and computer-aided design platform called Cello to program logic circuit behaviors in cells. The ASKE opportunity will seek to support an ambitious expansion in the types of biological behaviors that can be engineered.
‍
Asimov’s approach will leverage “multi-omics” cellular measurements, structured biological metadata, and novel AI architectures that combine deep learning, reinforcement learning, and mechanistic modeling. Over the past year, the company has ramped up hiring in experimental synthetic biology, machine learning, and data science to accelerate development of their genetic design platform.

Highlights

Headering 3

DARPA recently announced a multi-year investment of $2B into innovative artificial intelligence research called the AI Next campaign. A part of this wide-ranging AI strategy is DARPA’s Artificial Intelligence Exploration program, which was developed to help expeditiously move pioneering AI research from idea to exploration in fewer than 90 days. DARPA’s ASKE opportunity is part of this program and is focused on developing AI technologies that can reason over rich models of complex systems.

“Over the past 50 years, DARPA has been a world leader in spurring innovation across the field of AI, including statistical-learning and rule-based approaches. We are proud to work with DARPA to advance the state-of-the-art in AI-assisted genetic engineering.”

Alec Nielsen, PhD, Asimov CEO
This is some text inside of a div block. Great
Contact us

Chat with our team

Country
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form

Related posts

Blog
announcement
science & technology
Lonza and Asimov Collaborate to Advance In Vivo Lentiviral Vector Manufacturing

Lonza and Asimov Collaborate to Advance In Vivo Lentiviral Vector Manufacturing

Lonza and Asimov Collaborate to Advance In Vivo Lentiviral Vector Manufacturing

October 2, 2026
October 2, 2026
Blog
announcement
science & technology
Minaris and Asimov Partner to Advance AAV Manufacturing with OXGENE Technology

Minaris and Asimov Partner to Advance AAV Manufacturing with OXGENE Technology

Minaris and Asimov Partner to Advance AAV Manufacturing with OXGENE Technology

September 24, 2026
September 24, 2026
Blog
announcement
science & technology
Asimov Announces Cell Line Development Partnership with Sidewinder Therapeutics to Advance 4-Chain Bispecific Antibody for Solid Tumors

Asimov Announces Cell Line Development Partnership with Sidewinder Therapeutics to Advance 4-Chain Bispecific Antibody for Solid Tumors

Asimov Announces Cell Line Development Partnership with Sidewinder Therapeutics to Advance 4-Chain Bispecific Antibody for Solid Tumors

September 14, 2026
September 14, 2026
let’s CONNECT

Excited by the intersection of biology, engineering,
and machine learning?
Get in touch.

Asimov team at their Boston office
Illustration of a white blood cell